← Back to Clinical Trials
Recruiting NCT06438952

NCT06438952 Efficacy and Duration of Pain Relief in Transforaminal and Lumbar Sympathetic Blocks

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06438952
Status Recruiting
Phase
Sponsor Bezmialem Vakif University
Condition Low Back Pain
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-06
Primary Completion 2024-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Transforaminal steroid injection combined with lumbar sympathetic blockadeTransforaminal steroid injection only

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-06 with a primary completion date of 2024-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Low back pain is a symptom that is frequently seen in the general population and reduces the quality of life of patients. Conventional medical treatment for patients with low back pain includes oral medication, lifestyle modification, education, exercises, lumbar traction and manual manipulation, heat application, and other interventional procedures. Epidural injections, one of the interventional procedures, are one of the common treatment methods for low back pain, especially caused by disc prolapse. Steroids are commonly used to reduce inflammation in the epidural space. Epidural steroid injection can be given to the lumbar epidural space via transforaminal, interlaminar and caudal routes, and the effectiveness rate of each is different. These interventional methods used to treat low back pain can be applied in combination. The main purpose of this study is to observe how adding lumbar sympathetic blockade will affect the patient's pain in the postoperative period in patients to whom we applied caudal epidural and transforaminal steroid injection.

Eligibility Criteria

Inclusion Criteria: * ASA I-II-III * Patients who underwent facet joint injection and transforaminal injection due to lumbar disc herniation Exclusion Criteria: * Patients with known allergies to the drugs to be used in treatment * Infection near the puncture site * Known coagulation disorders * Patients with internal fixation or severe anatomical variation such as scoliosis and tumor * History of sympathetic chemical or thermal neurolysis * Alcohol and drug use * Disorder of consciousness * Liver failure, renal failure, advanced cardiac failure * Uncontrolled diabetes mellitus * Morbid obesity (body mass index (BMI) \> 35 kg m-2) * Female patients during pregnancy and breastfeeding * Not approving the informed consent form

Contact & Investigator

Central Contact

Zübeyde Özdemir

✉ etikkurul@bezmialem.edu.tr

📞 +90 2125232288

Principal Investigator

Zübeyde Özdemir

STUDY CHAIR

ethics committee chairman

Frequently Asked Questions

Who can join the NCT06438952 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Low Back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06438952 currently recruiting?

Yes, NCT06438952 is actively recruiting participants. Contact the research team at etikkurul@bezmialem.edu.tr for enrollment information.

Where is the NCT06438952 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT06438952 clinical trial?

NCT06438952 is sponsored by Bezmialem Vakif University. The principal investigator is Zübeyde Özdemir at ethics committee chairman. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology